Enrolls First

Related by string. * enrolled . enroll . enrolling . enrolls . Enrolling . Enroller : QB Re Enrolls . GW enrolls . visit www.aa.com enroll . Enrolled Actuary . Enrolled Agents CPAs . Enrolled Nurses / fi rst . first . firsts . Firsts . FIRST . f irst : FIRST LOOK AT . First Quarter Results . First Amendment protects . RECENT FIRST ROUND HISTORY . First Baptist Church . First Amendment Establishment Clause * *

Related by context. All words. (Click for frequent words.) 85 Completes Enrollment 83 Completes Patient Enrollment 83 Initiates Phase II 82 Initiates Enrollment 82 Presents Positive 81 Initiates Clinical Trial 81 Receives Orphan Drug Designation 81 Begins Dosing 81 Licenses Novel 80 Announce License Agreement 80 Announces Dosing 80 Receives FDA Clearance 80 Announces FDA Clearance 80 Initiates Phase III 80 Files IND 79 Initiates Dosing 79 Announces Initiation 79 Submits Biologics License Application 79 Presents Preclinical Data 79 Gets FDA Clearance 78 Receives Milestone Payment 78 Commences Phase 77 Receives Approvable Letter 77 Submits NDA 77 FDA Clears 77 Therapeutic Competitors Companies 77 Initiates Clinical 76 Announces License Agreement 76 Submits IND 76 Initiates Phase 76 Presents Preclinical 76 Submits Response 76 Meets Primary Endpoint 76 Sign Licensing Agreement 76 Demonstrates Significant 76 Presents Positive Preclinical 76 Sinks Lower 76 Announces Licensing Agreement 76 Earns Milestone Payment 75 Files Shelf Registration Statement 75 Demonstrates Positive 75 Reveals Positive 75 Announce Merger Agreement 75 Initiates Clinical Trials 75 Sign License Agreement 75 BioSante Pharmaceuticals Announces 75 Announces Issuance 75 Pharma Merck Serono 75 Amends Agreement 75 Announce Licensing Agreement 75 IG HCR ;) CO 75 Phase 2b Clinical Trial 75 Granted Orphan Drug 75 Collaborators Present 74 Announce Collaboration Agreement 74 Signs Licensing Agreement 74 Receives Patent 74 Announces Successful Completion 74 Announce Initiation 74 Reports Preclinical Data 74 Receives Favorable 74 Receives Fast Track 74 Present Preclinical Data 74 Achieves Primary Endpoint 74 Completes Dosing 74 Successfully Completes Phase 74 Patient Enrollment 74 Submits Application 74 Completes Merger With 74 Initiates Phase 2b 74 Announces Poster Presentations 74 TM Aganocide 74 Inc. Nasdaq OXGN 74 Announces Presentation 74 Announces Tentative Approval 74 Welcomes Analyst Initiation 74 Genentech sanofi aventis 74 Announces Positive 74 R MSCRAMM 74 Receives Orphan Drug 73 Reports Positive 73 FDA Accepts 73 Successfully Completes Tender Offer 73 Announces Favorable 73 Receives Complete Response 73 Achieves Milestone 73 Receives NASDAQ 73 Novartis Novo Nordisk 73 Nasdaq XTLB 73 Therapeutic Competitors companiesandmarkets.com adEgemonye 73 Investigational Oral 73 Announces Publication 73 Launches Generic Version 73 Begins Clinical Trial 73 Phase IIb Clinical Trial 73 Files Patent Application 73 Clinical Trial Evaluating 73 Reacquires 73 Receives CE Marking 73 Drug Candidate 73 Phase III Clinical Trial 73 Initiate Phase III 73 Announces Stockholder Approval 73 Finalizes Acquisition 73 Q1 Loss Narrows 73 Announces Termination 73 Provides Update Regarding 73 Preclinical Data 73 Submits Supplemental 73 PRN FDA Approves 73 sanofi aventis Bayer Schering 73 Taro Receives 73 Awarded Patent 73 Improves Survival 73 Files Investigational 73 Novel Oral 73 Signs License Agreement 73 FDA Approves 72 Namenda Memantine HCl 72 INDICATED LOWER 72 Jumps Higher 72 Q2 Loss Narrows 72 Initiate Clinical Trial 72 Awarded Qualifying Therapeutic 72 Receives Positive 72 Obtains Exclusive License 72 Q3 Loss Widens 72 First Patient Enrolled 72 Regains Compliance 72 CybeRelease Decliners 72 Receive Milestone Payment 72 Begins Shipment 72 Obtains FDA 72 Vaccine Adjuvant 72 Acquires Exclusive 72 Completes Patient Enrolment 72 Announce Early Termination 72 Extends Collaboration 72 Patients Treated With 72 Successfully Completes Acquisition 72 Completes Tender Offer 72 Significantly Improves 72 First Patient Treated 72 Q4 Loss Narrows 72 Confirms Receipt 72 Regains NASDAQ 72 Patent Issued 72 Receives Conditional 72 JAK2 Inhibitor 72 includes Dideco CarboMedics 72 Genentech Wyeth Pharmaceuticals 72 Develop Novel 72 Settle Patent Dispute 72 Settles Litigation 72 Inc Therapeutic Competitors 72 Spectrum Pharmaceuticals Announces 72 Earnings Postmortem 72 Q4 Loss Widens 72 Receives Regulatory 72 Introduces Next Generation 72 Regains Full 72 Taglich Brothers Initiates Coverage 72 Phase III Trial 71 Shareholders Approve Acquisition 71 Announces Dismissal 71 Announces Immediate Availability 71 Board Unanimously Rejects 71 Mylan Receives Approval 71 Announces Adjournment 71 Reports Receipt 71 Secures Financing 71 Awarded Patents 71 Announces Signing 71 Q3 Loss Narrows 71 Settle Patent Litigation 71 Study Demonstrates 71 AUDIO PROVIDED BY 71 Commence Phase 71 Terminate Merger Agreement 71 Inc. www.micromet inc.com 71 Phase IIb Trial 71 FDA APPROVES 71 Receives Favorable Ruling 71 Study Evaluating 71 Combination REOLYSIN R 71 Announces Commencement 71 candidates Azedra TM 71 Signs Agreements 71 Paris IPN Euronext 71 Restructures Operations 71 Clinical Trial Results 71 Bullish Average Crossover 71 Subsidiary Enters 71 Aradigm Logo 71 Shareholders Approve Merger Agreement 71 Vitrasert R 71 Completes Merger 71 MONSTERSTOX.COM Monsterstox.com 71 pralatrexate injection folate analogue 71 Regains Compliance With 71 Drug Fails 71 Telik logo TELINTRA 71 REG1 Anticoagulation System 71 Launches Next Generation 71 Receives Notification 71 Introduces Enhanced 71 please visit http:/www.vandapharma.com 71 Q2 Loss Widens 71 Successfully Treats 71 Obtains Approval 71 Nasdaq MNKD focuses 71 FDA Okays 71 Merck OSI Pharmaceuticals 71 Expands Scientific Advisory 71 developing Bicifadine serotonin 71 Receives Positive Opinion 71 Successfully Closes 71 Announce Receipt 71 Stockholders Approve Merger 71 Bullish Technical Alert 71 Provides Guidance 71 Receives Tentative Approval 71 Announces Postponement 71 Immunomedics Announces 71 Enters Agreement 71 visit http:/www.mannkindcorp.com 71 Strengthens Balance Sheet 70 Obtains License 70 Appoints Seasoned 70 Nasdaq VNDA 70 Receives Notice 70 Finalizes Purchase 70 Hematology Molecular Pathology 70 Completes Previously Announced 70 markets HP Acthar 70 Closes Previously Announced 70 Receives CE 70 Crofelemer budesonide foam 70 Phase 2b Trial 70 Significantly Reduces 70 Patent Covering 70 CysDisplay R 70 Genentech GlaxoSmithKline 70 FDA Approvals 70 Secures Additional 70 Inc. NASDAQ SIRT 70 acute peptic ulcer 70 COMUNICADO DE 70 Announces Effective Date 70 Xcytrin R 70 Board Authorizes 70 Luveris R Ovidrel R 70 Successfully Concludes 70 Oral Calcitonin 70 CHEAP ONLINE PHARMACY LOW 70 Receives Clearance 70 Pivotal Study 70 Confirms Efficacy 70 Bearish Speculation 70 Boehringer Ingelheim MedImmune 70 Introduces Novel 70 Releases Next Generation 70 Acquire Assets 70 visit www.genenews.com 70 Attracting Bullish Investors 70 Puts Purchased 70 palonosetron hydrochloride Injection Dacogen 70 Announces Definitive Agreement 70 Extends Tender Offer 70 Colaris Colaris AP 70 Terminates Agreement 70 Phase IIa Clinical Trial 70 Benzinga Volume Movers 70 Announces Shareholder Approval 70 Strengthens Position 70 TO AVOID PREGNANCY WHILE 70 Flamel Technologies Announces 70 Updates Status 70 TRACON Pharmaceuticals 70 TRANSDUR ® 70 NDA Submission 70 Completes Initial 70 Terminates Merger Agreement 70 Milestone Payment 70 NewsBite Downgrade Puts Pressure 70 Bearish Average Crossover 70 Closes Acquisition 70 Announce Completion 70 Initiate Phase 70 Announce Collaboration 70 Introduces Revolutionary 70 Demonstrates Potential 70 OTCBB FCSC 70 Reports Profitable 70 5q MDS 70 THERAPEUTICS 70 Receives SFDA Approval 70 Vascular Disrupting Agent 70 Shareholders Approve Merger 70 Signs Merger Agreement 70 Jointly Announce 70 Shows Promise 70 SPL# Gel vaginal microbicide 70 Adopts Shareholder Rights 70 Completes Acquisitions 70 NASDAQ MNKD focuses 70 PROFILE CO 70 otcstockexchange.com 70 Enters Into Licensing Agreement 70 researches develops licenses 70 Unveils Revolutionary 69 Receives Shareholder Approval 69 Receives Unsolicited 69 AllPennyStocks.com Spotlights 69 Introduces Expanded 69 Consummates 69 Significantly Increases 69 Extends Expiration Date 69 Announce Expiration 69 Inc. ProMetic www.prometic.com 69 Other OTC MNDP 69 commercializing Loramyc ® 69 Pivotal Phase III 69 Successfully Completes 69 pharmacogenomic translational research 69 Reveals Receipt 69 Treatment Experienced 69 COMPLETES ACQUISITION OF 69 Closes Second Tranche 69 Ovitrelle R Serostim 69 Stockholders Approve Acquisition 69 NASDAQ ANGO leading 69 Closes Merger 69 Announce Commencement 69 ev3 logo 69 Acquires Assets 69 Schedules Fiscal 69 ATRA IV 69 INDICATED HIGHER 69 CRWESelect CRWESelect.com Highlights 69 Announces Enhancements 69 Subsidiary Receives 69 Announce Definitive Agreement 69 Nasdaq AVNC 69 Investigational Treatment 69 Completes Financing 69 Receives Conditional Approval 69 Completes Recapitalization 69 Initiates Voluntary Recall 69 Announces Early Termination 69 lead molecular radiotherapeutic 69 Mutually Agree 69 Announces Formation 69 First Patient Dosed 69 Net Loss Widens 69 Files Registration Statement 69 Restructures Debt 69 Bradmer Pharmaceuticals 69 endoscopic autofluorescence imaging 69 Myriad logo BRACAnalysis 69 Commences Phase III 69 Merck Serono Nycomed 69 NOTE POSIDUR ™ 69 Pruvel TM 69 Announces Divestiture 69 Announces Receipt 69 Licenses Patents 69 Abstract Accepted 69 OTCStockExchange.com Stock Alert 69 Sign Definitive Merger 69 Voluntarily Withdraw 69 R lenalidomide 69 BayStreet.ca Research Alert 69 Hsp# Inhibitor 69 Report companiesandmarkets.com adds 69 Q1 Loss Widens 69 Exercises Option 69 Patients Enrolled 69 Moving Average Crossover Alert 69 Identifies Potential 69 Calls Purchased 69 Completes Reverse Merger 69 Therapeutic Competitors Report 69 Nasdaq AEGR 69 Pivotal Trial 69 Downtrend Spotted 69 R Saizen R 69 Gets Bearish Confirmation 69 Announces Discontinuation 69 Biogen Genentech 69 Bristol Myers Squibb Celgene 69 Clinical Study Shows 69 markets COLAZAL 69 Teva Provides Update 69 Enters Into Agreement 69 Nasdaq EPCT 69 Syneron logo 69 Agonist MABA program 69 NASDAQ XTLB 69 novel proprietary KL4 69 Enters Into Definitive 69 Locteron combines 69 Previously Treated 69 SABER ™ 69 Net Loss Narrows 69 Acquires Controlling Interest 69 Appoints Experienced 69 Expands Portfolio 69 Signs Option Agreement 69 TM Drug Eluting 69 Corp. AMEX CVM 69 Host Fourth Quarter 69 Extend Collaboration 69 Amend Merger Agreement 69 Delivers Next Generation 69 Completes Private Placement 69 Files Shelf Registration 69 BIOTECHNOLOGY SOURCE 69 CONFERENCE CALLS EARNINGS SOURCE 69 Achieves Positive 69 Settles Patent Dispute 69 Completes Successful 69 Enters Into License Agreement 69 Announces Cancellation 69 Sets Record Date 69 Stockholders Approve 69 Inc. NASDAQ QLTI 69 Completes Reorganization 69 Veronate R 69 Pivotal Clinical Trial 69 Demonstrates Sustained 69 Patient Treated 69 Closes Acquisition Of 69 Receives Notice Regarding 68 Receives Stockholder Approval 68 vapreotide acetate 68 TRANSDUR ™ 68 manufactures minimally invasive 68 Medical Sorin Biomedica 68 TSX Delisting Review 68 FY# Loss Widens 68 Nasdaq HALO 68 Evaluate Strategic Alternatives 68 Corp. NASDAQ CYTR 68 Provides Shareholder 68 Inc. NASDAQ VSGN 68 Single Dose 68 Trial Evaluating 68 Host Third Quarter 68 thrombin component 68 Bearish MACD 68 AS CALL VOLUME 68 Closes Financing 68 Begins Shipping 68 Receives Notice Related 68 Nasdaq ANPI 68 Improves Outcomes 68 Equipment Deals 68 Receives Commitment 68 Receives Delisting Notice 68 Cephalon GlaxoSmithKline 68 Files Patents 68 Announce Settlement 68 Phase 2a Trial 68 Advanced Melanoma 68 Receives Notice From 68 DAY PATTERN FOR 68 Acquirer Company 68 Announce Licensing 68 Updates Guidance 68 Announces Additions 68 Completes Purchase Of 68 Exploring Strategic Alternatives 68 Inks Licensing Deal 68 Receives Anticipated 68 Options Trader Alert 68 Secures Funding 68 Reminds Shareholders 68 acetonide FA 68 TSX VENTURE SLX OTCBB 68 Launches Innovative 68 Nasdaq SMTS develops manufactures 68 CONFERENCE CALLS SOURCE 68 Declares Quarterly Dividends 68 Post Earnings Checkup 68 Patients Treated 68 diarrhea fatigue asthenia 68 Company website www.anormed.com 68 CE marked PROGENSA 68 R famotidine 68 Drug Shows Promise 68 Provides Clarification 68 Nasdaq MNKD focused 68 estrogen receptor beta agonist 68 Introduces Powerful 68 CRWEWallstreet.com Stock Report 68 Posts Wider Loss 68 WeissComm Partners +#-#-#-# 68 NASDAQ MIPI 68 Significantly Expands 68 THE TREND CONTINUES DOWN 68 pipeline ImmunoGen collaborators 68 interferon beta 1a infertility 68 Reports Inducement Grants 68 Provide Comprehensive 68 DARA logo 68 Severe Sepsis 68 NeutroPhase TM 68 Prolongs Survival 68 Commences Trading 68 DOWNWARD MOMENTUM LOOKS TO 68 Announces Underwriters Exercise 68 Bullish Speculation 68 VentiRx Pharmaceuticals 68 Announce Availability 68 Stock Upgraded 68 Achieves SAS 68 Reports Significantly Improved 68 Joins OTCQX 68 4SC AG ISIN DE# 68 developing ACAPODENE 68 Dyax logo 68 dedicated CHAT ROOM 68 Sanofi Aventis Schering Plough 68 Humanized Anti 68 Commences Tender Offer 68 FDA Warns 68 MEDAREX 68 Holds Annual Meeting 68 Introduces Breakthrough 68 Extends Maturity 68 Webcast Annual Meeting 68 Reschedules Fourth Quarter 68 Enters Into Collaboration 68 candidates Azedra 68 PROMUS R 68 please visit www.abraxane.com 68 evaluating picoplatin 68 erlotinib Tarceva R 68 Pharmaceuticals Initiates 68 Unveils Innovative 68 Announces Filing 68 FY# Loss Narrows 68 Receives URAC 68 Completes Buyout 68 Complicated Skin 68 Nasdaq TARG 68 Strengthens Leadership 68 Closes Sale 68 Explores Strategic Alternatives 68 Unveils Breakthrough 68 Rated Speculative Buy 68 Staphylococcus aureus Immune Globulin 68 Investigational Compound 68 Expand Relationship 68 CONTINUES UP 68 Novartis Organon 68 Kinase Inhibitor 68 XL# anticancer compounds 68 oncolytic virus therapies 68 Completes Transaction 68 Enters Oversold Territory 68 Expand Collaboration 68 Issues Guidance 68 Guides Inline 68 Takeda Kyowa Hakko Kirin 68 Releases Enhanced 68 RealPennies.com RealPennies.com 68 proprietary intranasal insulin 68 Receives Tentative FDA 68 molecular imaging radiopharmaceutical 68 Issued Patent 68 Endures Analyst Downgrade 68 Files Patent 68 delivers fluocinolone acetonide FA 68 SIX RO ROG 68 IND Filing 68 Wins Patent Infringement 68 ELADUR TM 68 Transgenomic Pharmacogenomics Services 68 cladribine Cladribine Tablets 68 Nasdaq PGNX 68 Adopts Stockholder Rights 67 STERIS Corporation Announces 67 Enters Into Exclusive 67 Confirms Commitment 67 HuCAL PLATINUM R 67 Shows Promise Against 67 OTCBB TDLP 67 please visit http:/www.atherogenics.com 67 Inc. Nasdaq TRMS 67 Enters Into Letter 67 Orally Active 67 SHAREHOLDERS ARE STRONGLY ADVISED 67 Clarifies Status 67 Inc. Amex PIP 67 Antitumor Activity 67 Winning Streak Continues 67 Expands Scope 67 Explore Strategic Alternatives 67 visit www.sciclone.com 67 Announces Preliminary 67 Strengthens Its 67 THE TREND CONTINUES LOWER 67 Phase 1b Clinical Trial 67 HCV Protease Inhibitor 67 please visit http:/www.supergen.com 67 CORTOSS R 67 Molecular Diagnostic Test 67 Assets Acquirer Company 67 Transcept Pharmaceuticals 67 Includes KCI proprietary 67 Develop Next Generation 67 Enters Into Strategic 67 Discontinues 67 Inc. OTCBB ECTE 67 particularly SANCTURA XR 67 #.# [026] 67 Ltd. OTCBB IMUC 67 Amends Terms 67 Dementia Related Psychosis 67 Executes Agreement 67 Q1 Adj 67 Completes Integration 67 Changes Ticker Symbol 67 THE HIGHEST FREE 67 TELINTRA R 67 topical antifungal product 67 Shows Promising 67 Achieves ISO #:# Certification [002] 67 R roscovitine CDK cyclin 67 PROMUS TM 67 Technicals Showing Bearish 67 Pivotal Phase 67 Sign Definitive Agreement 67 Terminates Contract 67 topical gel formulation 67 Commercializes 67 3M Completes Acquisition 67 Cypher Sirolimus 67 Pomerantz Law Firm 67 Receives Accreditation 67 CONTINUES LOWER 67 NASDAQ BSMD medical 67 Receives Certification 67 platform HDL Mimetic 67 Completes Second Tranche 67 Enters Into Merger Agreement 67 PRODUCT SOURCE 67 Files Definitive Proxy 67 Therapeutic Competitors 67 MANAGEMENT CHANGES SOURCE 67 Completes Divestiture 67 GlaxoSmithKline MedImmune 67 Invites Investors 67 Complete Merger 67 Commercialize 67 Nasdaq CLDX 67 -gamma secretase modulator 67 Receives Approval 67 NICE Recommends 67 Acquire Controlling Interest 67 Expands Relationship 67 Put Volume Surges 67 Completes Refinancing 67 Provides Comprehensive 67 acquires researches develops 67 Announces Stock Repurchase 67 Announces Departure 67 FOLOTYN ® 67 novel emulsion formulation 67 TURNING INSIGHTS INTO HOPE 67 Announces Completion 67 BULL IN 67 Unsolicited Proposal From 67 Reduces Risk 67 Announces Revised 67 Expanded Indication 67 Announces Definitive Merger 67 Announce Agreement 67 Hold Fourth Quarter 67 SWOT Analysis Aarkstore Enterprise 67 OTCBB HNAB 67 Stockholders Approve Merger Agreement 67 Announces Addition 67 LSE SHP.L 67 Canaccord Genuity Reiterates Buy 67 OTC BB PVCT 67 Debuts Next Generation 67 dihydrochloride Tablets 67 Unveils Groundbreaking 67 BULLISH MOVING AVERAGE CROSSOVER 67 Q2 Adj 67 Canaccord Genuity Maintains Hold 67 Enter Into 67 BEARISH MOVING AVERAGE CROSSOVER 67 Generic Version 67 HSR Waiting Period 67 Topline Results 67 promotes MERREM ® 67 Announces Record Date 67 Commence Trading 67 Successfully Launches 67 Retains CCG Investor Relations 67 corticotropin injection 67 Collaborates With 67 Announces Share Repurchase 67 Oral Fingolimod 67 Undisclosed Investors 67 IIROC Halt 67 Inc. Nasdaq IMGN 67 Announces Consummation 67 Introduces Innovative 67 operating subsidiary CytoSorbents 67 Completes Transition 67 Subsidiary Signs 67 rusalatide acetate 67 Announces Proposed Acquisition 67 Expands Relationship With 67 visit http:/www.PAREXEL.com 67 GOES FROM 67 IIROC Resume 67 please visit www.medicinova.com 67 DOWNGRADE ALERT WATCH FOR 67 Successfully Completed 67 targeted anticancer biopharmaceuticals 67 Enters Into Definitive Agreement 67 Upcoming Deadline 67 Arthritis Drug 67 Webcast Presentations 67 personalized cellular immunotherapy 67 Tezampanel 67 OTCBB CAEH 67 Through Glycoscience R 67 Successfully Treated 67 NYSE Amex YMI 67 TM Everolimus Eluting 67 Trend Continues Down 67 Updates Shareholders 67 product candidate Lpathomab 67 Bearish Pressure Building 67 INTERNATIONAL HOLDINGS INC. 67 FDA Clearance 67 Transdermal Patch 67 Nicotine Conjugate Vaccine 67 Launches Enhanced 67 bone marrow reticulin deposition 67 Anti Tumor Activity 67 % pramoxine HCl 67 Completes Purchase 67 Antibody Drug Conjugate 67 Attains 67 Shows Statistically Significant 67 Refractory Hodgkin Lymphoma 67 website www.celsion.com 67 Approve Merger 67 pentadentate logo R 67 OTCQB CTIX 67 STOCKHOLDERS SHOULD READ 67 Matrix Phase 2b 67 CoTherix logo 67 Canaccord Genuity Maintains Buy 67 Chronic Hepatitis C 67 Cypress Bioscience Inc 67 Vascular Grafts 67 Buy Privately Held 67 Introduce Next Generation 67 Inc. OTCBB CADM 67 www.otc advisors.com names 67 Amigal TM 67 RANK Ligand inhibitor 67 Completes Asset 67 Settles Patent Litigation 67 Systemic Delivery 67 markets Testim ® 67 Extends Reach 67 By JAMAAL ABDUL 67 MARKETING AGREEMENTS SOURCE 67 ELADUR ™ 67 Breakthroughstocks.net EXPLOSIVE news 67 UPWARD MOMENTUM LOOKS TO 67 Personalized Immunotherapy 66 Redhotpennystock.com Alert 66 products MKC# PP 66 Acquires Remaining Interest 66 INITIATES 66 Successfully Demonstrates 66 Announces Acquisition 66 Drug Eluting Coronary Stent 66 Announces Expanded 66 Bullish Engulfing Pattern 66 candidate XP# 66 Bone Augmentation Material 66 Adjunctive Therapy 66 Shareholders Approve Sale 66 S. Arzerra 66 Tyrosine Kinase Inhibitor 66 Nasdaq ZGEN 66 Schedules Webcast 66 Well Tolerated 66 HCl PEPCID ® famotidine 66 markets XIFAXAN ® 66 Provides Updates 66 Provides Preliminary 66 Aloxi ® 66 Frankfurt XMP 66 Wolf Haldenstein Investigating 66 label Lipofen R 66 Lupus Drug 66 MEK Inhibitor 66 www.nmtmedical.com 66 Collaborators Publish 66 oral nucleoside analogue 66 Stock Downgraded 66 Osteoporosis Drug 66 Renegotiates 66 release capsules FENTORA 66 NASDAQ AVEO biopharmaceutical 66 AS PUT VOLUME 66 FDA Approves Generic 66 Microwave Ablation System 66 Recent Trades 66 Named Exclusive Distributor 66 MKC# MT 66 Declares Qtr 66 Reconfirms 66 Announce Shareholder Approval 66 Announces Webcast 66 Submits Investigational 66 Amex PTN 66 www.ucb.com 66 OTCBB GNTA 66 Dose Ranging Study 66 Traders Hedging Bets 66 NicVAX TM 66 FDA Approves Novel 66 Q2 Profit Surges 66 Pegloticase 66 Renews Relationship 66 LOUISMO 66 ORLive Presents 66 PPD Declares 66 Further Validates 66 Announces Availability 66 Files Annual Report 66 Host Second Quarter 66 CALL VOLUME UP 66 Renews Agreement 66 Announces Non Brokered 66 Attains Gold Certified Partner 66 Host Teleconference 66 Launches Unique 66 AMEX KAL 66 developing adecatumumab 66 Wafer polifeprosan 66 Provectus Pharmaceuticals specializes 66 Inc. OTCBB CYKN 66 Brentuximab Vedotin SGN 66 THE TREND CONTINUES UP 66 CORP. ANNOUNCES 66 NASDAQ NURO 66 Kuvan R 66 signal detection CTSD 66 Successfully Complete 66 Enzon Pharmaceuticals Inc 66 Announce Merger 66 Mg Usa 66 please visit www.dyax.com 66 Takeda Kyowa Hakko 66 AMEX RGN 66 Launches Groundbreaking 66 Embolic Protection 66 Gout Drug 66 Migraine Drug 66 Shareholders Elect 66 Finalizes Agreement 66 Unveils Latest 66 Resubmits 66 By JENNIFER LEARN 66 Proven Effective 66 Achieves Certification 66 Voluntarily Withdraws 66 Metastatic Melanoma 66 FOLFOX6 chemotherapy regimen 66 FEMALES SHOULD BE ADVISED 66 Completes Acquisition 66 SHAREHOLDERS APPROVE 66 Receives Approval From 66 Spins Out 66 Finalizes Sale 66 Cardioxyl Pharmaceuticals 66 visit http:/www.neogenomics.org 66 product platforms AZX# 66 Sets Second Quarter 66 ExxonMobil Fluor 66 Registration Statement Declared Effective 66 Transdermal System 66 THE TREND CONTINUES HIGHER 66 LES EXPLOSIFS NORDEX LTEE 66 Successfully Tested 66 'S LOSSES 66 Nasdaq IDIX 66 PHARM 66 programs visit http:/www.bionovo.com 66 Atripla combines 66 ASE SVA 66 visit www.targanta.com 66 :/ finance.yahoo.com q 66 Underwriters Exercise 66 Medisorb ® 66 Expands Capabilities 66 Posts Wider 66 Wins Approval 66 Receives Notification From 66 liver resection surgeries 66 Retains Leading 66 Patients Undergoing 66 developing ostarine selective 66 II Clinical Trial 66 Study Validates 66 please visit www.sucampo.com 66 Interesting Options Volume 66 NASDAQ SCRX specialty 66 Web Site http:/www.cryolife.com 66 Relapsed Multiple Myeloma 66 Release Capsules 66 Gel repository corticotropin injection 66 Newly Diagnosed Multiple Myeloma 66 Phase 2a Clinical Trial 66 TAXUS Element Paclitaxel Eluting 66 Retains Investor Relations 66 REPRONEX R menotropins 66 OTCBB URGP specialty 66 Maintains Strong 66 * vwd PRN 66 website http:/www.celsion.com 66 SERVICES INDUSTRY 66 Announce Exclusive 66 Announces Voluntary Recall 66 Declares Increase 66 widens Quick Facts 66 Broadens Its 66 MARKETING AGREEMENTS PRODUCT SOURCE 66 Enteral Feed Devices 66 LAST QUARTER ANNUALIZED SALES 66 Lowers Guidance 66 Announcement acc 66 SMARTREND DETECTS CONTINUED SELLING 66 Announces Closing 66 Receives CCHIT Certification 66 Inc. Nasdaq SUPG 66 ACQUIRES 66 Nasdaq UNIS 66 Marcus Gronholm BP 66 Nasdaq PPHM clinical 66 BCG refractory carcinoma 66 Sirna Therapeutics StrataCom 66 Lamotrigine Tablets 66 pan histone deacetylase 66 Uptrend Spotted 66 FREMONT CA #/#/# 66 2hours #mins #.#secs M 66 system vaporizes unformulated 66 Have Been Added 66 Therapy RecoveryRx TM 66 Settle Litigation 66 Unanimously Recommends Approval 66 Unveils Next Generation 66 Milestone Payment From 66 NYSE Amex PBTH 66 TriCo Bancshares Announces 66 Vertex Pharmaceuticals Announces 66 HuCAL PLATINUM ® CysDisplay 66 Completes Conversion 66 Announces Reverse Split 66 Concludes Acquisition 66 submitted supplemental Biologics 66 Nasdaq PARD 66 OctoPlus licensed 66 INC PRESENTS 66 OTCQX QRXPY 66 RELEASES ITS QUARTERLY NUMBERS 66 drugs FUSILEV 66 Idenix Novartis 66 Schedules Fourth Quarter 66 Receives Subpoena 66 Files Preliminary Prospectus 66 Aztreonam Lysine 66 evaluating intravenous picoplatin 66 Extends Relationship 66 Announces Reseller Agreement 66 Transdel Pharmaceuticals Inc. 66 Proposed Buyout 66 Q4 Profit Surges 66 ENTERS INTO 66 COLLABORATION WITH 66 Improves Quality 66 Schaeffer Sentiment Snapshot 66 TO EBITDA RATIO

Back to home page